REVIEW Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia Charles L. Bennett, MD, PhD Context The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepo- Samuel M. Silver, MD, PhD etin are licensed to treat chemotherapy-associated anemia in patients with nonmy- eloid malignancies. Although systematic overviews of trials have identified venous throm- Benjamin Djulbegovic, MD, PhD boembolism (VTE) risks, none have identified mortality risks with ESAs. Athena T. Samaras, BA Objective To evaluate VTE and mortality rates associated with ESA administration C. Anthony Blau, MD for the treatment of anemia among patients with cancer. Kara J. Gleason, BS Data Sources A published overview from the Cochrane Collaboration (search dates: January 1, 1985-April 1, 2005) and MEDLINE and EMBASE databases (key words: clini- Sara E. Barnato, MD cal trial, erythropoietin, darbepoetin, and oncology), the public Web site of the US Kathleen M. Elverman Food and Drug Administration and ESA manufacturers, and safety advisories (search D. Mark Courtney, MD dates: April 1, 2005-January 17, 2008). June M. McKoy, MD, MPH, JD Study Selection Phase 3 trials comparing ESAs with placebo or standard of care for the treatment of anemia among patients with cancer. Beatrice J.
JAMA – American Medical Association
Published: Feb 27, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.